2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-134361
    ATP-γ-S tetrasodium 88453-52-5 98%
    ATP-γ-S (tetrasodium) is a P2Y11 receptor agonist, an antioxidant and a neuroprotective agent. ATP-γ-S (tetrasodium) can be used as a substrate for the nucleotide hydrolysis and RNA unwinding activities of eukaryotic translation initiation factor eIF4A. ATP-γ-S (tetrasodium) is active in ATP hydrolysis.
    ATP-γ-S tetrasodium
  • HY-134425
    β-Methylcrotonyl coenzyme A lithium 108347-83-7 98%
    β-Methylcrotonyl coenzyme A lithium is an intermediate in leucine metabolism and can be used as a substrate to study the specificity and kinetics of β-methylcrotonyl coenzyme A carboxylase (MCCase).
    β-Methylcrotonyl coenzyme A lithium
  • HY-134438
    Hexanoyl coenzyme A trilithium 103476-19-3
    Hexanoyl coenzyme A trilithium is a hexanoyl-based medium-chain fatty acyl coenzyme A that is present in all organisms. Hexanoyl coenzyme A trilithium can be used as a precursor for cannabinoid biosynthesis and acts as a competitive inhibitor of medium-chain acyl coenzyme A dehydrogenase (MCAD).
    Hexanoyl coenzyme A trilithium
  • HY-13443S
    Exendin-4 (Leu-13C6,15N) TFA 98%
    Exendin-4 (Leu-13C6,15N) (Exenatide (Leu-13C6,15N)) TFA is the 13C- and 15N-labeled Exendin-4 TFA (HY-13443). Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.
    Exendin-4 (Leu-13C6,15N) TFA
  • HY-134522
    DL5050 2259710-64-8 98%
    DL5050 is a selective and potent human constitutive androstane receptor (hCAR) agonist that does not activate pregnane X receptor (PXR). DL5050 preferentially induces the expression of CYP2B6 (target of hCAR) over CYP3A4 (target of hPXR) on both the mRNA and protein levels. DL5050 can be used for the researches of cancer and metabolic disease, such as diabetes.
    DL5050
  • HY-13467A
    (R)-AM-1638 1142222-18-1 98%
    (R)-AM-1638 is a R-isomer of AM-1638 (HY-13467). AM-1638 is an orally active full agonist of GPR40 (EC50: 0.16 μM).
    (R)-AM-1638
  • HY-134917
    Aldi-2 499997-25-0 98%
    Aldi-2 is a potent and specific covalent inhibitor of aldehyde dehydrogenases (ALDHs) with IC50s of 2.5, 6.4 and 1.9 μM against ALDH1A1, ALDH2 and ALDH3A1, respectively. Aldi-2 can be utilized in cancer research.
    Aldi-2
  • HY-134960
    2,3-Indolobetulonic acid 905837-93-6 98%
    2,3-Indolobetulonic acid (compound 2), a triterpenoid, is α-glucosidase inhibitor with an IC50 of 1.8 µM.
    2,3-Indolobetulonic acid
  • HY-134969
    TFCA 895700-18-2 98%
    TFCA is a liver X receptor α (LXRα) antagonist. TFCA inhibits ligand-activated LXRα coactivation and transcriptional expression of the downstream target genes involved in fatty acid synthesis. TFCA attenuates ligand-induced lipogenesis and fatty liver by selectively inhibiting LXRα in the liver.
    TFCA
  • HY-134998
    Oltipraz metabolite M2 84201-40-1 98%
    Oltipraz metabolite M2, an active metabolite of Oltipraz (HY-12519), is an orally active HIF-1α inhibitor. Oltipraz metabolite M2 increases mitochondrial fuel oxidation and inhibits lipogenesis in the liver by dually activating AMPK in high-fat diet (HFD)-fed mice. Oltipraz metabolite M2 can be used for hepatic steatosis and steatohepatitis research.
    Oltipraz metabolite M2
  • HY-135212
    Hydroxy ipronidazole 35175-14-5 98%
    Hydroxy ipronidazole (Ipronidazole-OH) is a metabolite of nitroimidazole antibiotics, such as ipronidazole (IPZ). Hydroxy ipronidazole may has similar mutagenic potential as the parent compound.
    Hydroxy ipronidazole
  • HY-13524A
    AG-1478 hydrochloride 170449-18-0 98%
    AG-1478 hydrochloride (Tyrphostin AG-1478 hydrochloride) is a selective EGFR tyrosine kinase inhibitor with IC50 of 3 nM. AG-1478 hydrochloride has antiviral effects against HCV and encephalomyocarditis virus (EMCV).
    AG-1478 hydrochloride
  • HY-135252
    N-Desbutyroyl acebutolol 57898-80-3 98%
    N-Desbutyroyl Acebutolol (compound Ⅲ) is a metabolite of Acebutolol (HY-17497).
    N-Desbutyroyl acebutolol
  • HY-135337
    Ethyl tosylcarbamate 5577-13-9 98.87%
    Ethyl tosylcarbamate is an intermediate in the synthesis of Gliclazide (G409877). Gliclazide is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 nM.
    Ethyl tosylcarbamate
  • HY-135373
    Desfluoro-atorvastatin 433289-84-0 98%
    Desfluoro-atorvastatin is an impurity of Atorvastatin. Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids.
    Desfluoro-atorvastatin
  • HY-135374
    (3R,5S)-Atorvastatin sodium 131275-93-9 98%
    (3R,5S)-Atorvastatin sodium is an impurity of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.
    (3R,5S)-Atorvastatin sodium
  • HY-135375
    O-Methyl Atorvastatin calcium 887196-29-4 98%
    O-Methyl Atorvastatin (hemicalcium) is an impurity of Atorvastatin. Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids.
    O-Methyl Atorvastatin calcium
  • HY-135406
    (3R,5R)-Rosuvastatin Lactone 1422954-11-7 98%
    (3R,5R)-Rosuvastatin Lactone is an isomer of Rosuvastatin Lactone.
    (3R,5R)-Rosuvastatin Lactone
  • HY-135473
    Chlormadinone 1961-77-9 98.09%
    Chlormadinone is an orally active anti-androgen agent. Chlormadinone improves intermittency, terminal dribbling, and urinary stream size and force. Chlormadinone can be used for the research of benign prostatic hyperplasia.
    Chlormadinone
  • HY-135586
    Raloxifene N-Oxide 195454-31-0 98%
    Raloxifene N-Oxide is a Raloxifene oxidative degradation product.
    Raloxifene N-Oxide
Cat. No. Product Name / Synonyms Application Reactivity